Vera: Two-Year Kidney Data Settle the Science; the Launch Curve Now Sets the Price

Our view

Vera's case has moved from a clinical question to a commercial one. Today's ORIGIN 3 final efficacy analysis delivered what the June 2026 FDA alignment set up: eGFR stabilization through two years, a 76% reduction in composite kidney-disease-progression events and no dialysis, transplant or death events on drug against eight on placebo, with safety generally comparable to placebo. [1, 9] We regard the confirmatory science as largely settled, pending the congress presentation and the sBLA review.

What the market now pays for is a launch. At Monday's $34.05 close the basic capitalization was about $2.45 billion and enterprise value roughly $2.0 billion, before any product revenue has been reported. [4, 19] The disclosed launch metric, more than 350 patient start forms in ten weeks, is an intake number, not a prescription, a paid claim or revenue. [1] The next several quarters turn on conversion from start form to paid, persistent patient, and on whether two-year outcomes take share from five other approved IgAN therapies, two of which carry their own two-year eGFR data. [23, 26] The case is unresolved: the science met its bar; the economics have not been measured.

Starting market state

Last completed session, Monday, September 14: close $34.05, down 2.9% on 1.71 million shares, 0.8 times the 20-session average of 2.14 million (about $72 million a day). Five-session return -5.1%, 20-session +7.7%, 120-session -16.4%. Six-month intraday range $28.86-$47.00; 52-week range $22.72-$56.05, so the stock entered today about 39% below its 52-week high. [19, 20]

Premarket, September 15 (Yahoo one-minute bars; premarket volumes are not reported): $37.88 at 11:19:32Z, +11.2% against Monday's close, range $33.71-$39.93 to that point; by the 11:46:33Z bar the last print was $38.50 and the range had extended to $41.00. These are dated premarket observations, not a session close or a completed reaction. [18]

Capitalization on 72,063,335 shares (July 29 cover count): about $2.45 billion at the close and $2.73 billion at the 11:19Z print. June 30 cash, cash equivalents and marketable securities were $499.2 million against $75.0 million of Oxford term debt, so enterprise value is roughly $2.03 billion at the close and $2.31 billion at the premarket print. [4] StockAnalysis displayed short interest of 19.87 million shares, 27.6% of shares outstanding, with no verifiable settlement date. [17]

What changed

Announcement date: September 15, 2026, on the wire at 06:32 ET and in a Form 8-K (Items 7.01, 8.01, 9.01, with a 32-page slide deck as EX-99.2) accepted at 06:45:34 ET and confirmed on the issuer's live press-release index. Economic-event date: the 104-week ORIGIN 3 data cut, which the release does not date. Date learned: today. [1, 2, 3, 28]

Endpoints, final analysis set of 428 patients: mean eGFR change at 52 weeks -0.1 versus -5.7 mL/min/1.73m2 (treatment effect 5.6, p<0.0001); annualized eGFR slope through 104 weeks -0.6 versus -5.6; composite progression events 11 versus 38 (hazard ratio 0.24, 95% CI 0.12-0.48); dialysis of 30 days or more, transplant or death 0 versus 8. Proteinuria, Gd-IgA1 and hematuria were significant in hierarchical testing. Infections were 32% versus 28%. [1]

Status: TRUTAKNA (atacicept-vymj) received accelerated approval on July 7, 2026, to reduce proteinuria in adults with primary IgAN at risk of progression; the label says long-term slowing of kidney-function decline has not been established. [1, 6, 7] The company plans an sBLA for full approval in Q4 2026 and calls full approval a potential 2027 event. Since approval it has generated over 350 patient start forms in ten weeks and is seeing paid claims. [1] Pricing is not in today's filing; a July 11 Yahoo Finance account of the launch call reported a wholesale acquisition cost of $32,700 per four-dose carton, about $425,000 a year at list, and 82 sales representatives. [8]

Insiders: CEO Marshall Fordyce's September 2 Form 144 covers 64,750 shares from option exercises over three months under a 10b5-1 plan adopted January 9, 2026; he sold 18,500 shares that day at a weighted $35.12, and the chief accounting officer exercised 5,000 options on September 11 with no sale reported. Small, pre-planned, uninformative about today's data. [12, 13, 14]

Expectations

What was anticipated: after the June 2, 2025 36-week interim, two-year results were expected in 2027; on June 2, 2026 Vera announced FDA alignment on an earlier final analysis with results in Q3 2026 and an sBLA in Q4, and the stock fell 7.9% that day. [9, 10, 19] Today's announcement arrived on schedule; what was new was the magnitude. [1]

Guidance, consensus and our assumptions, kept apart. Guidance: sBLA in Q4 2026, potential full approval 2027, no revenue guidance, no conversion metric behind the start forms. [1, 5] Consensus: no dated sell-side revenue consensus was retrievable. StockAnalysis, a vendor aggregate retrieved at 11:48Z, displayed 2026 revenue of $24.8 million, 2027 revenue of $221.2 million and a 14-analyst average target of $77.36; a Benzinga item dated September 8 reported J.P. Morgan raising its target to $83. These are unverified third-party figures, not our estimates. [15, 16]

Our scenarios, labeled as ours, trace customer funding from demand to dilution. Demand: 350 forms in ten weeks is about 35 a week from an estimated 160,000 diagnosed U.S. patients. [5] Revenue: if 60% of forms become paid patients and net price is 65-75% of list, 210 persistent patients represent roughly $58-67 million of annualized net revenue; 1,000 would represent $275-320 million. Cash: first-half operating cash use was $206.8 million and Q2 net loss $109.5 million, so $499.2 million covers about four to five quarters at that rate before revenue, before the $20.0 million Ares milestone triggered by approval, and before the $75.0 million Oxford tranche available until November 4, 2026. [4] Dilution: 7,058,824 shares were sold at $42.50 in December 2025 for $281.3 million net, and a $200 million at-the-market agreement was unused as of the 10-Q; management states cash is sufficient for at least twelve months. [4, 11] The launch curve, not the sBLA, decides whether the next raise happens from strength or necessity.

Observed response

The observable response so far is premarket only: +11.2% at 11:19:32Z on a result whose date was known and whose magnitude was not. [18] It does not tell us whether the buying was short covering, long initiation or attention flow, and we make no claim about which. [17]

Two prior VERA data days frame the range. June 2, 2025 (36-week interim): +67.5% on 13.25 million shares, then a 30% decline over the next five sessions including -25.9% on June 6, a day with no VERA filing whose cause we did not establish. July 7, 2026 (approval): +7.1% on 5.13 million shares, then +0.4% over the following five. [19] Today is closer in kind to the second. We record the completed session and the five-session window before saying anything about persistence.

Comparable history and its limits

The ChartLibrary state packet for the last completed session (requested and returned 2026-09-14) classified VERA as down/below/off/stuck/ordinary/weak/crowd_in and returned 300 analogs across 173 symbols and 203 sessions, matched on market state and chart shape, sector unavailable. The historical distribution of excess returns that followed those states: five sessions p10 -8.2%, median +0.6%, p90 +10.7%, up 54.3% of the time; ten sessions p10 -11.7%, median +0.3%, p90 +17.4%. The five-session band was 2.1 times the base-rate width, which the packet labels informative. This is the memory's record of what followed similar states, sized as a band: it says nothing about direction, and the state was measured before today's news, so it is not conditioned on a data readout. [20]

Our nearest own comparable, the September 14 ARMP note, covered a regulatory milestone at a going-concern company with $0.4 million of daily dollar volume; VERA has an approved product, $499 million of cash and $72 million of daily dollar volume, and its catalyst closes a question rather than opening one. [4, 19]

Competitive facts, dated: Tarpeyo (Calliditas) full approval December 20, 2023. [21] Filspari (Travere) full approval September 5, 2024, on two-year eGFR. [22] Fabhalta (Novartis) traditional approval July 17, 2026. [23] Novartis also holds Vanrafia and presented 124-week zigakibart (anti-APRIL) data in June 2026. [24, 27] Voyxact (Otsuka sibeprenlimab, anti-APRIL) accelerated approval November 26, 2025, with two-year VISIONARY eGFR stabilization and a rolling sBLA for traditional approval in a release dated July 1, 2026. [25, 26] The National Kidney Foundation counted six approved IgAN therapies as of August 2026. [27] Vertex's June 1, 2026 povetacicept BLA-acceptance release could not be opened and is treated as an unverified headline. Whether prescribers see dual BAFF and APRIL inhibition and a 76% event reduction as separable from sibeprenlimab's two-year result is the open comparison.

The countercase

The case against our caution is that these are the best two-year outcome data yet reported in IgAN: a hazard ratio of 0.24, no dialysis, transplant or death on drug, placebo-like safety and a once-weekly at-home injection. If that becomes a 2027 full-approval label, payer criteria loosen and the start-form rate compounds, then 350 forms in ten weeks is the start of a curve and $2.5-2.7 billion is a small multiple of a plausible peak. A 27.6% short interest and a stock 39% below its 52-week high supply mechanical fuel. [1, 17]

The case against the stock is commercial, not scientific. Six approved therapies compete for roughly 160,000 diagnosed patients, several oral, at least two with their own two-year eGFR data and larger commercial organizations. [23, 26, 27] A $425,000 list price invites tight prior-authorization criteria; today's label is proteinuria-based and full approval is a 2027 event. Burn near $100 million a quarter meets a $200 million ATM and a $75 million debt tranche, so a slow launch converts into dilution or leverage. June 2025 shows how fast a VERA rally can reverse, and the result has been on the calendar since June 2, 2026, which makes a sell-the-news outcome as plausible as follow-through. [4, 9, 19]

What would change our view

Our view weakens if the completed September 15 session or the five-session window gives back the premarket gain on above-average volume without new information, if the congress presentation shows heterogeneity by baseline eGFR or proteinuria that narrows the eligible population, or if the sBLA slips out of Q4 2026.

Our caution is wrong if the next quarterly report shows start forms converting at a high rate into paid, persistent patients with recognized revenue annualizing materially above the vendor-displayed 2026 figure, if payer policies are disclosed as broad rather than restricted, or if the launch is funded without an ATM draw. A price cut or a competitor label claiming a similar hard-endpoint benefit would count against differentiation.

What we will revisit

Record the completed September 15 regular session (close, volume against the 2.14 million-share average, position in the day's range) and append it here; review September 22 (five sessions, counting today as one) and September 29 (ten). Watch for the congress presentation of the full ORIGIN 3 analysis, the sBLA submission in Q4 2026, the Q3 report in November with the first recognized TRUTAKNA revenue, any draw on the $75 million Oxford tranche before November 4, 2026, ATM usage in the Q3 10-Q, and further 10b5-1 sales under the September 2 Form 144. VERA passes our $25 million daily dollar-volume guideline; this note creates no model position and no entry instruction. The issuer's investor presentation page was not machine-accessible at the check time, and the 32-page results deck attached to the 8-K was not parsed; those remain a coverage gap.